论文部分内容阅读
公司是我国中药现代化的龙头企业。公司的拳头产品复方丹参滴丸已进入稳定期,连续几年的含税销售额均保持在10亿元左右,从今年前三季度的业绩情况看,我们预计该产品全年的增长率将超过10%。除了复方丹参滴丸和中药粉针剂,公司投入最大的新产品当属抗血栓新药重组人尿激酶原(RH-PROUK)。糖尿病纯中药产品消渴清颗粒已于今年3月获得新药证书和注册批件,目前已经上市。另一个寄予厚望的新产品板蓝根泡腾片也将在09年上市。
The company is the leading enterprise of Chinese medicine modernization. The company’s leading product compound Danshen dripping pills has entered a stable period, including tax sales for several years were maintained at 1 billion yuan, from the performance of the first three quarters of this year, we expect the annual growth rate of the product will exceed 10%. In addition to compound Danshen dripping pills and traditional Chinese medicine powder injection, the largest new product invested by the company was the new antithrombotic recombinant human prourokinase (RH-PROUK). Diabetes pure Chinese medicine Xiaoke Qing particles in March this year, a new drug certificate and registration documents, has been listed. Another high hopes of new products Banlangen effervescent tablets will be listed in 2009.